Amphastar Pharmaceuticals Inc. Common Stock (AMPH)
Stock · NASDAQ · Health Care
$25.87as of 10/16/2026
Price chart
Active signals
AMPH Signal Track Record
How signals performed across all stocks →What AMPH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -0.2% | 50% | September 18, 2026 |
| Bollinger Band Breakout | 26 | -3.4% | 42% | September 24, 2026 |
| Bollinger Band Breakdown | 21 | -4.5% | 29% | May 8, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +4.1% | 54% | August 31, 2026 |
| Any 20-session window (baseline) | -0.5% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of interm…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,976
- Website
- amphastar.com/
Fundamentals
- 1-day range
- $25.97$27.8
- Market cap
- $873.48M
- P/E (trailing)
- 14.15
- P/E (forward)
- 8.61
- EPS (trailing)
- $1.71
- Dividend yield
- —
- Beta
- 0.96
- Avg. volume
- 457.8K
How Amphastar Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Amphastar Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AMPHAmphastar Pharmaceuticals Inc. Common Stock$25.87▼ 2.08%Market cap $873.48MP/E 14.15$16.65$29.52
- DSGNDesign Therapeutics Inc. Common Stock$10.31▼ 1.62%Market cap $861.75MP/E —$5.28$17.25
- ACRSAclaris Therapeutics Inc. Common Stock$3.28▼ 6.02%Market cap $850.55MP/E —$1.74$6.6
- ABUSArbutus Biopharma Corporation Common Stock$4.22▼ 1.63%Market cap $896.82MP/E 5.55$3.5$5.45
- ANNXAnnexon Inc. Common Stock$3.41▼ 5.28%Market cap $917.52MP/E —$2.54$7.18
- KURAKura Oncology Inc. Common Stock$9.08▼ 6.39%Market cap $823.83MP/E —$7.36$13.9
- MNPRMonopar Therapeutics Inc. Common Stock$69.27▼ 3.52%Market cap $805.29MP/E —$50.07$124.82
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals Inc. Common Stock | $873.48M | 14.15 | $25.87 | ▼ 2.08% | $16.65$29.52 |
| DSGN Design Therapeutics Inc. Common Stock | $861.75M | — | $10.31 | ▼ 1.62% | $5.28$17.25 |
| ACRS Aclaris Therapeutics Inc. Common Stock | $850.55M | — | $3.28 | ▼ 6.02% | $1.74$6.6 |
| ABUS Arbutus Biopharma Corporation Common Stock | $896.82M | 5.55 | $4.22 | ▼ 1.63% | $3.5$5.45 |
| ANNX Annexon Inc. Common Stock | $917.52M | — | $3.41 | ▼ 5.28% | $2.54$7.18 |
| KURA Kura Oncology Inc. Common Stock | $823.83M | — | $9.08 | ▼ 6.39% | $7.36$13.9 |
| MNPR Monopar Therapeutics Inc. Common Stock | $805.29M | — | $69.27 | ▼ 3.52% | $50.07$124.82 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 3 Reasons to Avoid AMPH and 1 Stock to Buy InsteadYahoo · 9/24/2026
- 3 Russell 2000 Stocks We Find RiskyYahoo · 9/21/2026
- 3 Small-Cap Stocks with Warning SignsYahoo · 9/18/2026
- Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals GroupYahoo · 9/17/2026
Insider Activity
Insider Actions →- William J. Peters · September 21, 2026 · Sale4.1K @ $25
- Rong Zhou · September 16, 2026 · Option Exercise10.0K @ $13.35
- Rong Zhou · September 16, 2026 · Sale10.0K @ $23.94
- Rong Zhou · September 2, 2026 · Sale3.2K @ $23.63
- Richard K. Prins · August 11, 2026 · Sale8.0K @ $20.3
- William J. Peters · August 7, 2026 · Option Exercise5.1K @ $19.79
- William J. Peters · August 7, 2026 · Sale8.2K @ $22.48
- Anthony T. Pierce · July 9, 2026 · Grant16.6K
- Anthony T. Pierce · July 9, 2026 · Grant7.9K
- Howard Lee · June 2, 2026 · Tax Withholding769 @ $18.45
- Richard K. Prins · June 1, 2026 · Grant8.1K
- Michael A. Zasloff · June 1, 2026 · Grant17.4K
- David Russell Gaugh · June 1, 2026 · Grant17.4K
- David Russell Gaugh · June 1, 2026 · Grant8.1K
- Gayle Deflin · June 1, 2026 · Grant17.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 30.92M
- Total value held
- $583.89M
- Institutional holders
- 206
- Unknown5.42M
- Unknown2.03M
- Unknown1.61M
- Unknown1.54M
- Unknown1.54M
- Unknown1.40M
- Unknown1.03M
- Unknown1.02M
- Unknown976.6K
- Unknown944.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Amphastar (AMPH) Cited as Safe-and-Steady Stock in Yahoo Analysis
A recent Yahoo Finance article highlighted Amphastar Pharmaceuticals as a 'safe-and-steady' stock worth researching further. This positive framing contrasts with other companies facing challenges, suggesting the market views AMPH as a relatively stable option. The stock currently trades with a trailing P/E of 14.2, which is lower than the average analyst target price of $22.50.
Amphastar (AMPH) Cited as Safe-and-Steady Stock in Yahoo Analysis. A recent Yahoo Finance article highlighted Amphastar Pharmaceuticals as a 'safe-and-steady' stock worth researching further. This positive framing contrasts with other companies facing challenges, suggesting the market views AMPH as a relatively stable option. The stock currently trades with a trailing P/E of 14.2, which is lower than the average analyst target price of $22.50.